Minimally invasive nephron-sparing treatments for T1 renal cell cancer in patients over 75 years: a comparison of outcomes after robot-assisted partial nephrectomy and percutaneous ablation.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 18 11 2022
accepted: 28 05 2023
revised: 17 05 2023
medline: 27 11 2023
pubmed: 19 7 2023
entrez: 19 7 2023
Statut: ppublish

Résumé

To compare the oncological and perioperative outcomes of robot-assisted partial nephrectomy (RPN) and percutaneous thermal ablation (PTA) for treatment of T1 renal cell cancer (RCC) in patients older than 75 years. Retrospective national multicenter study included all patients older than 75 years treated for a T1 RCC by RPN or PTA between January 2010 and January 2021. Patients' characteristics, tumor data, and perioperative and oncological outcomes were compared. A total of 205 patients for 209 procedures (143 RPN and 66 PTA) were included. In the PTA group, patients were older (80.4 ± 3.7 vs. 79 ± 3.7 years (p = 0.01)); frailer (ASA score (2.43 ± 0.6 vs. 2.17 ± 0.6 (p < 0.01)); and more frequently had a history of kidney surgery (16.7% [11/66] vs. 5.6% [8/143] (p = 0.01)) than in the RPN group. Tumors were larger in the RPN group (2.7 ± 0.7 vs. 3.2 ± 0.9 cm (p < 0.01)). Operation time, length of hospital stay, and increase of creatinine serum level were higher in RPN (respectively 92.1 ± 42.7 vs. 150.7 ± 61.3 min (p < 0.01); 1.7 ± 1.4 vs. 4.2 ± 3.4 days (p < 0.01); 1.9 ± 19.3% vs. 10.1 ± 23.7 (p = 0.03)). Disease-free survival and time to progression were similar (respectively, HR 2.2; 95% CI 0.88-5.5; p = 0.09; HR 2.1; 95% CI 0.86-5.2; p = 0.1). Overall survival was shorter for PTA that disappeared after Cox adjusting model (HR 3.3; 95% CI 0.87-12.72; p = 0.08). Similar oncological outcomes are observed after PTA and RPN for T1 RCC in elderly patients. Robot-assisted partial nephrectomy and percutaneous thermal ablation have similar oncological outcomes for T1a kidney cancer in patients over 75 years; however, operative time, decrease in renal function, and length of hospital stay were lower with ablation. • After adjusting model for age and ASA score, similar oncological outcomes are observed after percutaneous thermal ablation and robot-assisted partial nephrectomy for T1 renal cell cancer in elderly patients. • Operation time, length of hospital stay, and increase of creatinine serum level were higher in the robot-assisted partial nephrectomy group.

Identifiants

pubmed: 37466710
doi: 10.1007/s00330-023-09975-5
pii: 10.1007/s00330-023-09975-5
doi:

Substances chimiques

Creatinine AYI8EX34EU

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8426-8435

Informations de copyright

© 2023. The Author(s), under exclusive licence to European Society of Radiology.

Références

Ljungberg B, Albiges L, Abu-Ghanem Y et al (2019) European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 75:799–810
doi: 10.1016/j.eururo.2019.02.011 pubmed: 30803729
Campbell S, Uzzo RG, Allaf ME et al (2017) Renal mass and localized renal cancer: AUA guideline. J Urol 198:520–9
doi: 10.1016/j.juro.2017.04.100 pubmed: 28479239
Thompson RH, Atwell T, Schmit G et al (2015) Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 67:252–9
doi: 10.1016/j.eururo.2014.07.021 pubmed: 25108580
Zhou M, Mills A, Noda C, Ramaswamy R, Akinwande O (2018) SEER study of ablation versus partial nephrectomy in cT1A renal cell carcinoma. Future Oncol Lond Engl 14:1711–9
doi: 10.2217/fon-2017-0678
Yan S, Yang W, Zhu C-M, Yan P-M, Wang Z-C (2019) Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2 cm or sized 2–4 cm: a population-based study. Medicine (Baltimore) 98:15610
doi: 10.1097/MD.0000000000015610
Anglickis M, Anglickienė G, Andreikaitė G, Skrebūnas A (2019) Microwave thermal ablation versus open partial nephrectomy for the treatment of small renal tumors in patients over 70 years old. Medicina (Kaunas) 55:664
doi: 10.3390/medicina55100664 pubmed: 31581459
Xing M, Kokabi N, Zhang D, Ludwig JM, Kim HS (2018) Comparative effectiveness of thermal ablation, surgical resection, and active surveillance for T1a renal cell carcinoma: a Surveillance, Epidemiology, and End Results (SEER)–Medicare-linked population study. Radiology 288:81–90
doi: 10.1148/radiol.2018171407 pubmed: 29737950
Uhlig J, Kokabi N, Xing M, Kim HS (2018) Ablation versus resection for stage 1A renal cell carcinoma: national variation in clinical management and selected outcomes. Radiology 288:889–97
doi: 10.1148/radiol.2018172960 pubmed: 29969077
Cholley I, Correas JM, Masson-Lecomte A et al (2018) Comparison of operative and oncologic results between partial nephrectomy and radiofrequency ablation for treatment of renal tumors in patients older than 75. Prog Urol 28:55–61
doi: 10.1016/j.purol.2017.10.006 pubmed: 29174691
Kutikov A, Egleston BL, Wong Y-N, Uzzo RG (2010) Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 28:311–7
doi: 10.1200/JCO.2009.22.4816 pubmed: 19933918
Kutikov A, Egleston BL, Canter D, Smaldone MC, Wong Y-N, Uzzo RG (2012) Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol 188:2077–83
doi: 10.1016/j.juro.2012.07.100 pubmed: 23083850 pmcid: 4659779
Morkos J, Porosnicu Rodriguez KA et al (2020) Percutaneous cryoablation for stage 1 renal cell carcinoma: outcomes from a 10-year prospective study and comparison with matched cohorts from the National Cancer Database 296:452–9
Cornelis F, Balageas P, Le Bras Y et al (2012) Radiologically-guided thermal ablation of renal tumours. Diagn Interv Imaging 93:246–61
doi: 10.1016/j.diii.2012.02.001 pubmed: 22464994
Peyronnet B, Seisen T, Oger E et al (2016) Comparison of 1800 robotic and open partial nephrectomies for renal tumors. Ann Surg Oncol 23:4277–83
doi: 10.1245/s10434-016-5411-0 pubmed: 27411552
Ingels A, Duc S, Bensalah K et al (2021) Postoperative outcomes of elderly patients undergoing partial nephrectomy. Sci Rep 11:17201
doi: 10.1038/s41598-021-96676-y pubmed: 34433877 pmcid: 8387350
Babbar P, Hemal AK (2012) Robot-assisted partial nephrectomy: current status, techniques, and future directions. Int Urol Nephro 44:99–109
doi: 10.1007/s11255-011-9900-6
Antonelli A, Cozzoli A, Zani D et al (2007) The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 99:296–300
doi: 10.1111/j.1464-410X.2006.06616.x pubmed: 17326263
Park BK, Gong IH, Kang MY et al (2018) RFA versus robotic partial nephrectomy for T1a renal cell carcinoma: a propensity score-matched comparison of mid-term outcome. Eur Radiol 28:2979–85
doi: 10.1007/s00330-018-5305-6 pubmed: 29426988
Tanagho YS, Bhayani SB, Kim EH, Figenshau RS (2013) Renal cryoablation versus robot-assisted partial nephrectomy: Washington University long-term experience. J Endourol 27:1477–86
doi: 10.1089/end.2013.0192 pubmed: 24283518
Cholley I, Correas J, Sanchez S et al (2015) Comparaison de la chirurgie conservatrice vs ablation par radiofréquence pour le traitement du carcinome à cellules rénales après 75ans. Prog En Urol 25:827–8
doi: 10.1016/j.purol.2015.08.220
Lane BR, Gill IS (2007) 5-year outcomes of laparoscopic partial nephrectomy. J Urol 177(70–4):74
pubmed: 17162003
Park BK, Shen S-H, Fujimori M, Wang Y. (2021) Thermal ablation for renal cell carcinoma: expert consensus from the Asian Conference on Tumor Ablation. Korean J Radiol 22,(9):1490
Andrews JR, Atwell T, Schmit G et al (2019) Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 76:244–51
doi: 10.1016/j.eururo.2019.04.026 pubmed: 31060824
Pantelidou M, Challacombe B, McGrath A et al (2016) Percutaneous radiofrequency ablation versus robotic-assisted partial nephrectomy for the treatment of small renal cell carcinoma. Cardiovasc Intervent Radiol 39:1595–603
doi: 10.1007/s00270-016-1417-z pubmed: 27435582 pmcid: 5052326
Yoon YE, Lee HH, Kim KH et al (2018) Focal therapy versus robot-assisted partial nephrectomy in the management of clinical T1 renal masses: a systematic review and meta-analysis. Medicine (Baltimore) 97:13102
doi: 10.1097/MD.0000000000013102
Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H (2014) Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 65:372–7
doi: 10.1016/j.eururo.2013.06.044 pubmed: 23850254
Garcia RG, Katz M, Falsarella PM et al (2021) Percutaneous cryoablation versus robot-assisted partial nephrectomy of renal T1A tumors: a single-center retrospective cost-effectiveness analysis. Cardiovasc Intervent Radiol 44:892–900
doi: 10.1007/s00270-020-02732-x pubmed: 33388867
De Marini P, Cazzato RL (2021) Garnon J et al Safety and oncologic efficacy of percutaneous MRI-guided cryoablation of intraparenchymal renal cancers. Diagn Interv Imaging. 102:531–538
doi: 10.1016/j.diii.2021.04.002 pubmed: 33931365

Auteurs

Raphaël Lehrer (R)

Department of Radiology, Sorbonne Université, AP-HP, Hôpital Tenon, Paris, France.
Department of Interventional Radiology, Sorbonne Université, Paris, France.

Francois Cornelis (F)

Radiology Department, Memorial Sloan Kettering Cancer Center, New York, USA.
French Research Network on Kidney Cancer UroCCR, Bordeaux, France.

Jean-Christophe Bernhard (JC)

French Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Department of Urology, Hôpital Pellegrin, Bordeaux University Hospital, Bordeaux, France.

Pierre Bigot (P)

French Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Department of Urology, Angers University Hospital, Angers, France.

Cécile Champy (C)

Department of Urology, University Hospital Henri Mondor, AP-HP, Créteil, France.
INSERM, U1430, Henri Mondor University Hospital, AP-HP, 94000, Creteil, France.

Franck Bruyère (F)

French Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Department of Urology, Tours University Hospital, Tours, France.

Morgan Rouprêt (M)

French Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Department of Urology, Pitié-Salpêtrière Hospital, Sorbonne University, AP-HP, Paris, France.

Nicolas Doumerc (N)

French Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Department of Urology, University Hospital Rangueil, Toulouse, France.

Charles-Karim Bensalah (CK)

French Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Department of Urology, Rennes University Hospital, Rennes, France.

Jonathan Olivier (J)

Department of Urology, Lille University Hospital, Lille, France.

François Audenet (F)

French Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Department of Urology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Thibault Tricard (T)

Department of Urology, Nouvel Hôpital Civil, Strasbourg, France.

Bastien Parier (B)

Department of Urology, Bicêtre University Hospital, AP-HP, Le Kremlin-Bicêtre, France.

Xavier Durand (X)

Department of Urology, Paris Saint-Joseph Hospital, Paris, France.

Matthieu Durand (M)

Department of Urology, Hôpital Pasteur 2, Nice, France.
INSERM U1081 - CNRS, UMR 7284, Université de Nice Côte d'Azur, Nice, France.

Thomas Charles (T)

French Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Department of Urology, Poitiers University Hospital, Poitiers, France.

Nicolas Branger (N)

Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France.

Louis Surlemont (L)

Department of Urology, Rouen University Hospital, Rouen, France.

Evanguelos Xylinas (E)

French Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Paris, France.

Jean-Baptiste Beauval (JB)

French Research Network on Kidney Cancer UroCCR, Bordeaux, France.
Department of Urology, Grenoble University Hospital, Grenoble, France.

Matthias Barral (M)

Department of Radiology, Sorbonne Université, AP-HP, Hôpital Tenon, Paris, France. matthias.barral@aphp.fr.
Department of Interventional Radiology, Sorbonne Université, Paris, France. matthias.barral@aphp.fr.
Service d'Imagerie Radiologiques et Interventionnelles Spécialisées, Hôpital Tenon, Sorbonne Université, AP-HP, 4 rue de la chine, 75020, Paris, France. matthias.barral@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH